QUOTED. 26 November 2019. Jonathan Phillips.
Court rulings related to the False Claims Act (FCA) this year focused on whistleblower rules and further clarifying the theory of liability given in the Supreme Court's 2016 Escobar decision. Device manufacturers, however, should also be aware of the FDA's ongoing focus on the opioid epidemic. See what Jonathan Phillips, an attorney with Gibson Dunn, said about it here.
“The whole health-care apparatus wrapping around the manufacture and sale of opioids seems to be an issue, and I think we'll see a number of enforcement efforts in the next year.” – Jonathan Phillips, attorney, Gibson Dunn
Click here for a free trial of Medtech Insight